Abstract | UNLABELLED:
Paclitaxel has fared poorly in clinical trials against brain glioma. We hypothesized that superparamagnetic nanocarriers may enhance its bioactivities by delivering it into the brain. MATERIALS AND METHODS: The magnetic paclitaxel nanoparticles (MPNPs) were fabricated and their cytotoxicity against glioma was tested both in vitro and in glioma-bearing rats. RESULTS: MPNPs exhibited superparamagnetism and produced an extended release of paclitaxel over 15 days in vitro. They were easily internalized into glioma cells and exerted remarkable toxicity, as free paclitaxel did. Furthermore, after intravenous injection of MPNPs to glioma-bearing rats and magnetic targeting with a 0.5 T magnet, drug content increased for 6- to 14-fold in implanted glioma and 4.6- to 12.1-fold in the normal brain compared to free paclitaxel. The survival of glioma-bearing rats was significantly prolonged after magnetic targeting therapy with MPNPs. CONCLUSION:
|
Authors | Ming Zhao, Chao Liang, Anmin Li, Jin Chang, Hanjie Wang, Runmin Yan, Jiajing Zhang, Junli Tai |
Journal | Anticancer research
(Anticancer Res)
Vol. 30
Issue 6
Pg. 2217-23
(Jun 2010)
ISSN: 1791-7530 [Electronic] Greece |
PMID | 20651372
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents, Phytogenic
- Paclitaxel
|
Topics |
- Animals
- Antineoplastic Agents, Phytogenic
(administration & dosage)
- Brain Neoplasms
(drug therapy, mortality, pathology)
- Cell Line, Tumor
- Cerebral Cortex
(metabolism)
- Glioma
(drug therapy, mortality, pathology)
- Humans
- Magnetics
- Nanoparticles
(administration & dosage)
- Paclitaxel
(administration & dosage, chemistry, metabolism)
- Rats
- Rats, Sprague-Dawley
- Solubility
- Xenograft Model Antitumor Assays
|